(296) Variations in the Retail Price of Human Chorionic Gonadotropin in the United States

Abstract

Abstract Introduction Urine-derived human chorionic gonadotropin (HCG) remains a popular treatment for hypogonadotropic hypogonadism and induction of spermatogenesis or puberty in select patients. Shortages in both brand name and generic HCG, and the resulting increases in prices, have raised barriers in the treatment of patients. Objective To determine the variations in the price of HCG therapy within the U.S. and the potential for the undue financial burden on patients receiving HCG therapy. Methods Using the GoodRx website, prices of generic HCG, Pregnyl, and Novarel (10,000-unit vial) with and without coupons were recorded. Prices were collected from the most popular retail pharmacies in each state’s most populous zip code. The lowest and highest retail prices were noted for each brand by state and pharmacy. Results The mean highest retail prices for generic HCG, Pregnyl, and Novarel were $546.42 ± $64.95, $170.28 ± $76.82, and $387, respectively. The mean lowest retail prices of generic HCG, Pregnyl, and Novarel were $289.68, $113.88 ± $1.29, and $307.31 ± $2.00, respectively. The mean difference between the highest and lowest prices available within the same zip code for generic HCG, Pregnyl, and Novarel were $256.74 ± $64.95, $54.40 ± $76.65, and $79.69 ± $2.00, respectively (Figure 1). Conclusions Differences between the highest and lowest prices available for HCG therapy within a set zip code reached $462 per vial, demonstrating the potential for the undue financial burden on patients receiving HCG therapy. Significant changes in the cost of HCG therapy were seen within zip codes as a result of pricing differences between brands and pharmacies. Despite this, there was no significant variation in the lowest price available for generic HCG therapy between states. Given these price variations, providers must be aware of pricing patterns and be able to assist patients as they navigate the financials of these treatments. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Antares Pharma; Clarus Therapeutics; Cynosure; Promescent; Sprout; Viome.